Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 632

1.

Validation of SCT Methylation As a Hallmark Biomarker for Lung Cancers.

Zhang YA, Ma X, Sathe A, Fujimoto J, Wistuba II, Lam S, Yatabe Y, Wang YW, Stastny V, Gao B, Larsen JE, Girard L, Liu X, Song K, Behrens C, Kalhor N, Xie Y, Zhang MQ, Minna JD, Gazdar AF.

J Thorac Oncol. 2015 Dec 24. pii: S1556-0864(15)00052-0. doi: 10.1016/j.jtho.2015.11.004. [Epub ahead of print]

PMID:
26725182
2.

From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers.

Gazdar AF, Hirsch FR, Minna JD.

J Thorac Oncol. 2015 Dec 24. pii: S1556-0864(15)00031-3. doi: 10.1016/j.jtho.2015.10.009. [Epub ahead of print] Review.

3.

Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma.

Soh J, Toyooka S, Matsuo K, Yamamoto H, Wistuba II, Lam S, Fong KM, Gazdar AF, Miyoshi S.

Oncol Lett. 2015 Sep;10(3):1775-1782. Epub 2015 Jun 23.

4.

Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer.

Hubaux R, Thu KL, Vucic EA, Pikor LA, Kung SH, Martinez VD, Mosslemi M, Becker-Santos DD, Gazdar AF, Lam S, Lam WL.

Int J Cancer. 2015 Nov 1;137(9):2072-82. doi: 10.1002/ijc.29577. Epub 2015 May 6.

PMID:
25907283
5.

Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival.

Schliekelman MJ, Taguchi A, Zhu J, Dai X, Rodriguez J, Celiktas M, Zhang Q, Chin A, Wong CH, Wang H, McFerrin L, Selamat SA, Yang C, Kroh EM, Garg KS, Behrens C, Gazdar AF, Laird-Offringa IA, Tewari M, Wistuba II, Thiery JP, Hanash SM.

Cancer Res. 2015 May 1;75(9):1789-800. doi: 10.1158/0008-5472.CAN-14-2535. Epub 2015 Mar 5.

PMID:
25744723
6.

The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung.

Gazdar AF, Savage TK, Johnson JE, Berns A, Sage J, Linnoila RI, MacPherson D, McFadden DG, Farago A, Jacks T, Travis WD, Brambilla E.

J Thorac Oncol. 2015 Apr;10(4):553-64. doi: 10.1097/JTO.0000000000000459.

PMID:
25675280
7.

Genetic mutation of p53 and suppression of the miR-17∼92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin D Signaling.

Borkowski R, Du L, Zhao Z, McMillan E, Kosti A, Yang CR, Suraokar M, Wistuba II, Gazdar AF, Minna JD, White MA, Pertsemlidis A.

Cancer Res. 2015 Feb 15;75(4):666-75. doi: 10.1158/0008-5472.CAN-14-1329. Epub 2014 Dec 17.

PMID:
25519225
8.

Proteomic signatures associated with p53 mutational status in lung adenocarcinoma.

Taguchi A, Delgado O, Celiktaş M, Katayama H, Wang H, Gazdar AF, Hanash SM.

Proteomics. 2014 Dec;14(23-24):2750-9. doi: 10.1002/pmic.201400378. Epub 2014 Nov 20.

9.

ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.

Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, Lee V, Tan C, Sullivan JP, Larsen JE, Girard L, Behrens C, Wistuba II, Xie Y, Cobb MH, Gazdar AF, Johnson JE, Minna JD.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14788-93. doi: 10.1073/pnas.1410419111. Epub 2014 Sep 29.

10.

A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets.

Taguchi A, Taylor AD, Rodriguez J, Celiktaş M, Liu H, Ma X, Zhang Q, Wong CH, Chin A, Girard L, Behrens C, Lam WL, Lam S, Minna JD, Wistuba II, Gazdar AF, Hanash SM.

Cancer Res. 2014 Sep 1;74(17):4694-705. doi: 10.1158/0008-5472.CAN-13-3725. Epub 2014 Jun 26.

11.

Analysis of TP53 mutation status in human cancer cell lines: a reassessment.

Leroy B, Girard L, Hollestelle A, Minna JD, Gazdar AF, Soussi T.

Hum Mutat. 2014 Jun;35(6):756-65. doi: 10.1002/humu.22556. Epub 2014 May 6. Review.

12.

Methylation analysis in spontaneous sputum for lung cancer diagnosis.

Hubers AJ, van der Drift MA, Prinsen CF, Witte BI, Wang Y, Shivapurkar N, Stastny V, Bolijn AS, Hol BE, Feng Z, Dekhuijzen PN, Gazdar AF, Thunnissen E.

Lung Cancer. 2014 May;84(2):127-33. doi: 10.1016/j.lungcan.2014.01.019. Epub 2014 Jan 31.

PMID:
24598366
13.

Radiation-enhanced lung cancer progression in a transgenic mouse model of lung cancer is predictive of outcomes in human lung and breast cancer.

Delgado O, Batten KG, Richardson JA, Xie XJ, Gazdar AF, Kaisani AA, Girard L, Behrens C, Suraokar M, Fasciani G, Wright WE, Story MD, Wistuba II, Minna JD, Shay JW.

Clin Cancer Res. 2014 Mar 15;20(6):1610-22. doi: 10.1158/1078-0432.CCR-13-2589. Epub 2014 Jan 31.

14.

EGFR mutations in lung cancer: different frequencies for different folks.

Gazdar AF.

J Thorac Oncol. 2014 Feb;9(2):139-40. doi: 10.1097/JTO.0000000000000063. No abstract available.

PMID:
24419408
15.

Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer.

Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE, Zubovych I, Seo BY, Kim J, Eskiocak B, Chung H, McMillan E, Wu S, De Brabander J, Komurov K, Toombs JE, Wei S, Peyton M, Williams N, Gazdar AF, Posner BA, Brekken RA, Sood AK, Deberardinis RJ, Roth MG, Minna JD, White MA.

Cell. 2013 Oct 24;155(3):552-66. doi: 10.1016/j.cell.2013.09.041. Epub 2013 Oct 24.

16.

YEATS4 is a novel oncogene amplified in non-small cell lung cancer that regulates the p53 pathway.

Pikor LA, Lockwood WW, Thu KL, Vucic EA, Chari R, Gazdar AF, Lam S, Lam WL.

Cancer Res. 2013 Dec 15;73(24):7301-12. doi: 10.1158/0008-5472.CAN-13-1897. Epub 2013 Oct 29.

17.

The pivotal role of pathology in the management of lung cancer.

Davidson MR, Gazdar AF, Clarke BE.

J Thorac Dis. 2013 Oct;5 Suppl 5:S463-78. doi: 10.3978/j.issn.2072-1439.2013.08.43. Review.

18.

EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk.

Wilson IM, Vucic EA, Enfield KS, Thu KL, Zhang YA, Chari R, Lockwood WW, Radulovich N, Starczynowski DT, Banáth JP, Zhang M, Pusic A, Fuller M, Lonergan KM, Rowbotham D, Yee J, English JC, Buys TP, Selamat SA, Laird-Offringa IA, Liu P, Anderson M, You M, Tsao MS, Brown CJ, Bennewith KL, MacAulay CE, Karsan A, Gazdar AF, Lam S, Lam WL.

Oncogene. 2014 Sep 4;33(36):4464-73. doi: 10.1038/onc.2013.396. Epub 2013 Oct 7.

19.

Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer.

Coe BP, Thu KL, Aviel-Ronen S, Vucic EA, Gazdar AF, Lam S, Tsao MS, Lam WL.

PLoS One. 2013 Aug 15;8(8):e71670. doi: 10.1371/journal.pone.0071670. eCollection 2013.

20.

Precision medicine for cancer patients: lessons learned and the path forward.

Gazdar AF, Minna JD.

J Natl Cancer Inst. 2013 Sep 4;105(17):1262-3. doi: 10.1093/jnci/djt219. Epub 2013 Aug 20. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk